ArticleCellular oncology (Dordrecht, Netherlands)2026
PDIA6 exacerbates hepatocellular carcinoma via enhancing proteasome-dependent degradation of AKAP12.
Article in Cellular oncology (Dordrecht, Netherlands), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
The continuously rising incidence and persistently high mortality of hepatocellular carcinoma (HCC) have created an urgent need for a deeper understanding of the molecular mechanisms underlying this disease. In the present study, leveraging multiple HCC transcriptome databases, we employed expression analysis, correlation analysis, Gene Set Variation Analysis (GSVA), and cox regression analysis to identify that aberrant upregulation of PDIA6 represents a promising prognostic biomarker associated with adverse clinical outcomes in HCC. Using a series of in vitro oncology research approaches, as well as nude mouse models of subcutaneous tumor formation and lung metastasis, we experimentally validated that PDIA6 promotes the proliferation and metastasis of HCC cells. Through transcriptome sequencing analysis and subsequent rescue experiments, we further confirmed that PDIA6 enhances HCC cell proliferation and migration by activating the Wnt signaling pathway. Combined analysis via immunoprecipitation-mass spectrometry and proteomics revealed that PDIA6 significantly downregulates the expression of the tumor suppressor gene AKAP12. Subsequent rescue experiments demonstrated that PDIA6 drives HCC progression in a manner dependent on the reduced expression of AKAP12. Utilizing protein half-life assays, ubiquitination assays, and co-IP experiments, we uncovered the underlying mechanism: PDIA6 competitively binds to the UCH domain of USP24, which impairs the deubiquitinating activity of USP24 towards AKAP12. This ultimately leads to enhanced K48-linked ubiquitination of AKAP12 and its subsequent proteasomal degradation. We further verified, using specific activators, that AKAP12 inhibits the Wnt signaling pathway in a PKA-dependent manner. In vivo, targeted inhibition of PDIA6 exhibited a more potent therapeutic effect on Wnt-positive HCC tumors.Conclusion Collectively, our study demonstrates the HCC-promoting mechanism of the PDIA6-AKAP12-Wnt signaling axis and highlights its great potential for the development of therapeutic targets in HCC.
Indexed as
Identifiers
42420688What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.